Bisdemethoxycurcumin Inhibits Hepatocellular Carcinoma Proliferation Through Akt Inactivation via CYLD-Mediated Deubiquitination

References

• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• MaluccioM, CoveyA. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394–399. doi:10.3322/caac.2116123070690
   PubMed Web of Science ®Google Scholar
• DuttaR, MahatoRI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106–117. doi:10.1016/j.pharmthera.2017.02.01028174094
   PubMed Web of Science ®Google Scholar
• ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• ZhuAX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006;11(7):790–800. doi:10.1634/theoncologist.11-7-79016880238
   PubMed Web of Science ®Google Scholar
• CarrBI. Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004;127(5 Suppl 1):S218–24. doi:10.1053/j.gastro.2004.09.03615508087
   PubMed Web of Science ®Google Scholar
• TomehMA, HadianamreiR, ZhaoX. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci. 2019;20(5). doi:10.3390/ijms20051033
   PubMed Web of Science ®Google Scholar
• BasileV, FerrariE, LazzariS, BellutiS, PignedoliF, ImbrianoC. Curcumin derivatives: molecular basis of their anti-cancer activity. Biochem Pharmacol. 2009;78(10):1305–1315. doi:10.1016/j.bcp.2009.06.10519580791
   PubMed Web of Science ®Google Scholar
• LiYB, GaoJL, ZhongZF, HoiPM, LeeSM, WangYT. Bisdemethoxycurcumin suppresses MCF-7 cells proliferation by inducing ROS accumulation and modulating senescence-related pathways. Pharmacol Rep. 2013;65(3):700–709. doi:10.1016/S1734-1140(13)71048-X23950593
   PubMed Web of Science ®Google Scholar
• LiuYL, YangHP, ZhouXD, GongL, TangCL, WangHJ. The hypomethylation agent bisdemethoxycurcumin acts on the WIF-1 promoter, inhibits the canonical Wnt pathway and induces apoptosis in human non-small-cell lung cancer. Curr Cancer Drug Targets. 2011;11(9):1098–1110.21933103
   PubMed Web of Science ®Google Scholar
• LuoC, DuZ, WeiX, ChenG, FuZ. Bisdemethoxycurcumin attenuates gastric adenocarcinoma growth by inducing mitochondrial dysfunction. Oncol Lett. 2015;9(1):270–274. doi:10.3892/ol.2014.268525435973
   PubMed Web of Science ®Google Scholar
• PeiH, YangY, CuiL, et al. Bisdemethoxycurcumin inhibits ovarian cancer via reducing oxidative stress mediated MMPs expressions. Sci Rep. 2016;6:28773. doi:10.1038/srep2877327349797
   PubMed Web of Science ®Google Scholar
• LiaoCL, ChuYL, LinHY, et al. Bisdemethoxycurcumin suppresses migration and invasion of human cervical cancer HeLa cells via inhibition of NF-kB, MMP-2 and −9 pathways. Anticancer Res. 2018;38(7):3989–3997. doi:10.21873/anticanres.1268629970522
   PubMed Web of Science ®Google Scholar
• XuJ, YangH, ZhouX, WangH, GongL, TangC. Bisdemethoxycurcumin suppresses migration and invasion of highly metastatic 95D lung cancer cells by regulating E-cadherin and vimentin expression, and inducing autophagy. Mol Med Rep. 2015;12(5):7603–7608. doi:10.3892/mmr.2015.435626459909
   PubMed Web of Science ®Google Scholar
• YuJS, CuiW. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050–3060. doi:10.1242/dev.13707527578176
   PubMed Web of Science ®Google Scholar
• ChungW, KimM, de la MonteS, et al. Activation of signal transduction pathways during hepatic oncogenesis. Cancer Lett. 2016;370(1):1–9. doi:10.1016/j.canlet.2015.09.01626433160
   PubMed Web of Science ®Google Scholar
• BhaskarPT, HayN. The two TORCs and Akt. Dev Cell. 2007;12(4):487–502. doi:10.1016/j.devcel.2007.03.02017419990
   PubMed Web of Science ®Google Scholar
• LinK. The Akt DUBbed InAktive. Sci Signal. 2013;6(257):pe1. doi:10.1126/scisignal.200386423300338
   PubMed Web of Science ®Google Scholar
• YangWL, WuCY, WuJ, LinHK. Regulation of Akt signaling activation by ubiquitination. Cell Cycle. 2010;9(3):487–497. doi:10.4161/cc.9.3.1050820081374
   PubMed Web of Science ®Google Scholar
• YangWL, WangJ, ChanCH, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325(5944):1134–1138. doi:10.1126/science.117506519713527
   PubMed Web of Science ®Google Scholar
• ChanCH, LiCF, YangWL, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012;149(5):1098–1111. doi:10.1016/j.cell.2012.02.06522632973
   PubMed Web of Science ®Google Scholar
• LimJH, JonoH, KomatsuK, et al. CYLD negatively regulates transforming growth factor-beta-signalling via deubiquitinating Akt. Nat Commun. 2012;3:771. doi:10.1038/ncomms177622491319
   PubMed Web of Science ®Google Scholar
• LiuK, WuX, ZangX, et al. TRAF4 regulates migration, invasion, and epithelial-mesenchymal transition via PI3K/AKT signaling in hepatocellular carcinoma. Oncol Res. 2017;25(8):1329–1340. doi:10.3727/096504017X1487622728656428256185
   PubMed Web of Science ®Google Scholar
• NelsonKM, DahlinJL, BissonJ, GrahamJ, PauliGF, WaltersMA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620–1637. doi:10.1021/acs.jmedchem.6b0097528074653
   PubMed Web of Science ®Google Scholar
• ChenJ, LiL, SuJ, ChenT. Natural borneol enhances bisdemethoxycurcumin-induced cell cycle arrest in the G2/M phase through up-regulation of intracellular ROS in HepG2 cells. Food Funct. 2015;6(3):740–748. doi:10.1039/C4FO00807C25537301
   PubMed Web of Science ®Google Scholar
• ZhangW, LiuHT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12(1):9–18. doi:10.1038/sj.cr.729010511942415
   PubMed Web of Science ®Google Scholar
• SaekiY. Ubiquitin recognition by the proteasome. J Biochem. 2017;161(2):113–124. doi:10.1093/jb/mvw09128069863
   PubMed Web of Science ®Google Scholar
• RestucciaDF, HemmingsBA. Cell signaling. Blocking Akt-ivity. Science. 2009;325(5944):1083–1084. doi:10.1126/science.117997219713516
   PubMed Web of Science ®Google Scholar
• SuizuF, HiramukiY, OkumuraF, et al. The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev Cell. 2009;17(6):800–810. doi:10.1016/j.devcel.2009.09.00720059950
   PubMed Web of Science ®Google Scholar
• BignellGR, WarrenW, SealS, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000;25(2):160–165. doi:10.1038/7600610835629
   PubMed Web of Science ®Google Scholar
• YangWL, JinG, LiCF, et al. Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci Signal. 2013;6(257):ra3. doi:10.1126/scisignal.200319723300340
   PubMed Web of Science ®Google Scholar
• SunSC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 2010;17(1):25–34. doi:10.1038/cdd.2009.4319373246
   PubMed Web of Science ®Google Scholar
• GlittenbergM, LigoxygakisP. CYLD: a multifunctional deubiquitinase. Fly (Austin). 2007;1(6):330–332. doi:10.4161/fly.539918820455
   PubMed Web of Science ®Google Scholar